Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1997-3-14
|
pubmed:abstractText |
Mirfentanil [N-(2-pyrazinyl)-N-(1-phenethyl-4-piperidinyl)-2-furamide] was studied for its antinociceptive and immunomodulatory effects in mice Mirfentanil (1.0-32.0 mg/kg) increased tail-flick latency to a thermal stimulus and this effect was antagonized (94 +/- 2%) by naltrexone (10.0 mg/kg). Unlike naltrexone, the delta opioid selective antagonist naltrindole (20.0 mg/kg) had no effect on mirfentanil-induced analgesia. In a dose-dependent fashion, the mu-selective antagonists beta-funaltrexamine (1.0-40.0 mg/kg) and naloxonazine (1.0-35.0 mg/kg) blocked mirfentanil (10.0 mg/kg)-induced analgesia up to 75% of the maximum analgesic effect. Norbinaltorphimine (10.0 mg/kg) partially blocked (35%) the maximum analgesic effect following mirfentanil (10.0 mg/kg) administration. Single doses of mirfentanil (0.1-32.0 mg/kg) had no effect on splenic NK activity. However, preadministration of mirfentanil (1.0-10.0 mg/kg) blocked morphine-induced suppression of splenic NK activity. Collectively, the results suggest that mirfentanil is a novel opioid that induces antinociception predominately through mu opioid receptors but, unlike morphine or fentanyl, does not suppress splenic NK activity.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics,
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics, Opioid,
http://linkedlifedata.com/resource/pubmed/chemical/Fentanyl,
http://linkedlifedata.com/resource/pubmed/chemical/Morphine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid, mu,
http://linkedlifedata.com/resource/pubmed/chemical/mirfentanil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0162-3109
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
9-16
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8880221-Adjuvants, Immunologic,
pubmed-meshheading:8880221-Analgesics,
pubmed-meshheading:8880221-Analgesics, Opioid,
pubmed-meshheading:8880221-Animals,
pubmed-meshheading:8880221-Dose-Response Relationship, Drug,
pubmed-meshheading:8880221-Drug Interactions,
pubmed-meshheading:8880221-Female,
pubmed-meshheading:8880221-Fentanyl,
pubmed-meshheading:8880221-Killer Cells, Natural,
pubmed-meshheading:8880221-Mice,
pubmed-meshheading:8880221-Mice, Inbred ICR,
pubmed-meshheading:8880221-Morphine,
pubmed-meshheading:8880221-Receptors, Opioid, mu,
pubmed-meshheading:8880221-Spleen
|
pubmed:year |
1996
|
pubmed:articleTitle |
Mirfentanil antagonizes morphine-induced suppression of splenic NK activity in mice.
|
pubmed:affiliation |
Department of Microbiology, Immunology, Parasitology, Louisiana State University Medical Center, New Orleans 70112-1393, USA. dcarr@pop3.lsumc.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|